ArticleDNA and cell biology reports
Single-Cell RNA Sequencing Identifies CCR6-Driven Immune Landscape Changes in RM1 Prostate Cancer Bone Metastasis.
Article in DNA and cell biology reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Background: Prostate cancer commonly metastasizes to bone, creating an immunosuppressive microenvironment that supports tumor progression. The RM1 (Ras/Myc) mouse model is a valuable tool for studying interactions between prostate tumors and the bone marrow immune landscape. Methods: Single-cell RNA sequencing was employed to investigate how CCR6 deficiency affects immune cell comsmunication in bone marrow from RM1 prostate cancer bone metastasis. Immune responses were compared between wild-type and CCR6 knockout (CCR6ko) C57BL/6-mice injected with RM1-BoM3 cells. Results: Distinct immune cell dynamics were observed between the two groups. CCR6ko bone marrow showed enhanced signaling from macrophages, regulatory T cells, and myeloid-derived suppressor cell-like cells, with altered receptor activity in naïve T cells, NK cells, and conventional dendritic cells. Differential gene expression highlighted immune regulation pathways and transcriptional networks centered on JUN, JUNB, and FOSB, linked to immune suppression and tumor progression. Cell-cell communication analysis revealed changes in CCL, TGFb, MIF, and CXCL pathways, aligning with observations in human castration-resistant prostate cancer (CRPC) bone-metastasis. Profiling of immune cell populations showed increased tumor-infiltrating monocytic cells, M2 macrophages, and NKT-like CD8 cells in RM1 tumors compared to CCR6ko bone marrow. Pathway enrichment analysis identified upregulated pathways, including IL-17 signaling and osteoclast differentiation, associated with immune-modulation and inflammation. Gene regulatory networks in the RM1 bone metastasis microenvironment involved NFKB1, STAT1, IRF8, and JUN family proteins, emphasizing their roles in immune suppression and tumor progression. Conclusions: These results suggest that targeting CCR6 may enhance immunotherapy efficacy in prostate cancer bone metastasis by reshaping the immune microenvironment. Validation in human CRPC bone metastasis datasets revealed conserved immune interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.